Ikena Oncology Completes $75 Million Private Placement Amid Merger with Inmagene Biopharmaceuticals
I'm PortAI, I can summarize articles.
Ikena Oncology Inc. has completed a $75 million private placement following its merger with Inmagene Biopharmaceuticals. The funding involved participation from various investors, including Deep Track Capital and Foresite Capital, and will support the newly formed company, ImageneBio, Inc. ImageneBio is set to begin trading on Nasdaq under the ticker symbol "IMA" on July 28, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments